Terengganu/Penang, Malaysia – Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") recently held two coronary artery chronic total occlusion ("CTO") workshops in Malaysia, during which several experts presented live cases to show the excellent performance of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").
On February 5, MicroPort® held the first Coronary Artery CTO workshop in 2017 in Hospital Sultanah Nur Zahirah ("HSNZ") based in Terengganu of Malaysia. Professor Rosli Bin Mohd Ali, Chief Clinical Officer of IJN National Heart Institute, and Dr. Zulkifli Bin Mustapha of HSNZ completed a complex CTO case using MicroPort®'s new generation drug-eluting stent Firehawk®. The two experienced operators first predilated the lesion with FOXTROT™ PRO PTCA Balloon Dilatation Catheter ("FOXTROT® PRO") and then skillfully delivered Firehawk® to the lesion. After the operation, they spoke highly of Firehawk® and FOXTROT® PRO's outstanding crossability in tortuous lesions.
On February 17, MicroPort® held the second Coronary Artery CTO workshop in Hospital Tengku Ampuan Afzan ("HTAA") in Penang of Malaysia. Professor Dato' Dr. Wan Azman Bin Wan Ahmad, a senior cardiologist of University of Malaya, and Dr. Siti Khairani Binti Zainal Abidin, head of Cardiology Department of HTAA, demonstrated five CTO cases in which Firehawk®, FOXTROT® PRO, and FOXTROT® NC PTCA Balloon Dilatation Catheter ("FOXTROT® NC") were used. One of the most complex cases is a patient diagnosed with three vessel disease and CTO on LAD and meanwhile having several kinds of complications. Professor Wan was acutely aware of and well prepared for the difficulties in the operation and smoothly solved them to achieve successful result. During the case, Professor Wan also demonstrated the retrograde approach technique to young physicians in attendance.
Firehawk®'s excellent performance in treating CTO complex lesions has been well proven in the live cases of the two Coronary Artery CTO workshops. Meanwhile, the workshops allowed the attended physicians to get hands-on experience in Firehawk®, FOXTROT® PRO, and FOXTROT® NC, which will largely enhance their understanding and confidence in MicroPort® products.
"In 2017, MicroPort® will continue to work with Malaysian distributors to organize a series of workshops regarding the application of Firehawk® and other MicroPort® products in treating complex coronary artery lesions to strengthen the communication between physicians of China and Malaysia, and at the same time we will carry out relevant clinical studies in Malaysia to provide more high-quality medical solutions for patients with coronary artery diseases by evidence-based medicine," said Dr. Linda Lin, First Vice President of MicroPort® International Business.